Rocket Pharma Announces Clinical Safety Update Regarding Initial Three Patients Treated Under Modified Protocol For Global, Pivotal Phase 2 Trial Of RP-A501 In Danon Disease

Loading news article.

Rocket Pharma Announces Clinical Safety Update Regarding Initial Three Patients Treated Under Modified Protocol For Global, Pivotal Phase 2 Trial Of RP-A501 In Danon Disease | WAPE

Rocket Pharma Announces Clinical Safety Update Regarding Initial Three Patients Treated Under Modified Protocol For Global, Pivotal Phase 2 Trial Of RP-A501 In Danon Disease

Article summary

Related companies

Comments —